|
GLP1 RECEPTOR AGONISTS WITH INSULIN |
|
|
|
Background -
previous application by ABCD to MHRA re glitazone use with insulin |
|
|
|
In 2004-2005 the combination of glitazones and
insulin was contra-indicated. ABCD contacted the Medicines and
Healthcare Products Regulatory Agency (MHRA) putting the case that the
combination might nevertheless be used in certain cases under diabetes
specialist supervision. |
|
|
|
ABCD, MPS and MHRA documents with regard to glitazones and insulin in
combination |
|
|
|
In summary the MHRA response was:
"...In the meantime, as you are aware the
contraindication for use of glitazones in combination with insulin is not a
prohibition, and a physician may decide that for a particular patient in his
or her care, it is in the patient’s best interest. We consider this would be
only appropriate for physicians in special centres." |
|
|
|
At the time this was taken to give approval to
diabetologists to give the contra-indicated combination to particular
patients who the specialist thought might benefit. |
|
|
|
|
|
August 2011 - new
application by ABCD to MHRA re use of GLP1 receptor agonists with insulin |
|
|
|
ABCD have recently contacted MHRA again giving
data from our nationwide exenatide and liraglutide audits: |
|
|
|
ABCD
letter to MHRA re use of GLP1 receptor agonists with insulin |
|
Figures and tables that
were sent with the letter |
|
MHRA response to ABCD re
use of GLP1 receptor agonists with insulin |
|
|
|
In summary the MHRA response was:
"...The responsibility for the safety and
efficacy of this combination in patients in the UK lies with the prescribing
physician, preferably within a centre specializing in diabetes management"
ABCD feels that this response is similar to
that given with regard to the use of glitazones with insulin in 2005 - that
the combination would be most appropriately used by diabetes specialists |
